Dr. Prasad has served as Senior Vice President and Chief Medical Officer at Audentes Therapeutics since February 2014. He is a Paediatrician with a wide range of experience and achievements in international drug development across Phase I to IV, with a specific focus on the clinical development of innovative therapies to treat rare, paediatric disorders. Dr. Prasad has worked in medicines development in positions of increasing responsibility at BioMarin Pharmaceutical, Genzyme Corporation, and Eli Lilly and Company. He has broad therapeutic expertise in neuromuscular disease, metabolic medicine, bone metabolism, neuroscience, endocrinology, immunology, and genetics.
Dr. Prasad graduated in Medicine at the University of Newcastle-upon-Tyne, UK, where he received commendations for Paediatrics, Obstetrics and Gynaecology, and Medical Ethics. He is a United Kingdom board certified physician with a sub-specialty interest in Pediatric Critical Care. He is a member of the Royal College of Physicians (MRCP) and the Royal College of Paediatrics and Child Health (MRCPCH). He has a Masters in Translational Science from Kings College London, and has received his Diploma in Pharmaceutical Medicine from the Royal College. He is an elected Fellow to the Faculty of Pharmaceutical Medicine (FFPM) and is a past recipient of the Outstanding Contribution Award from the Faculty of Pharmaceutical Medicine of the UK Royal College of Physicians. Dr. Prasad sits on the board of the international patient organization, the National PKU Association.